Literature DB >> 12664356

[A new objective test for random-dot stereopsis in preverbal children].

Armin Breyer1, Xiaoyi Jiang, Adrian Rütsche, Daniel S Mojon.   

Abstract

BACKGROUND: The Lang-Stereotest is at best half-objective in testing stereovision in preverbal children. We developed a new method which might objectively measure random-dot stereopsis in preverbal children. PATIENTS AND METHODS: We project two separate random-dot images into the left and right eye using a 3D-monitor. If both eyes are perfectly aligned and random stereopsis is present, the child perceives a stimulus. Four different stimulus positions are shown at random. An infrared oculography system objectively detects whether the stimuli are seen. By using a specific baby examination unit, testing is already feasible in infants.
RESULTS: We present the plots of two children with a positive (normal) and two with a negative (pathologic) response to random-dot stimuli.
CONCLUSIONS: This new examination technique allows an objective assessment of random-dot stereopsis in non-verbal children. It permits us for the first time to study the development of stereovision under natural conditions. In future, the method may also be used to screen preverbal children for visual abnormalities. Larger studies are required to determine the positive and negative predictive values of this new test.

Entities:  

Mesh:

Year:  2003        PMID: 12664356     DOI: 10.1055/s-2003-38164

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  2 in total

1.  Performance of a new, 3D-monitor based random-dot stereotest for children under 4 years of age.

Authors:  Birgitta Kriegbaum-Stehberger; Xiaoyi Jiang; Daniel S Mojon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-03       Impact factor: 3.117

2.  [Nintendo 3DS: technology, physiology and possible risks for children's eyes].

Authors:  A Pallas; C H Meyer; D Mojon
Journal:  Ophthalmologe       Date:  2013-03       Impact factor: 1.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.